RudaCure has established RudaCure U.S.A. Inc. to expand its presence in the United States.
The U.S. subsidiary is expected to serve as the headquarters for future U.S. clinical trials of RCI002, as well as to attract U.S. local investments under the Bio iCORE project, develop U.S. grants, and act as a forward base for open innovation.
The U.S. address is 40W. 37th St. Suite 801, New York, NY 10018.